Standing tracker · snapshot
UK MHRA regulatory modernisation — Health Bill tracker
On 1 September the UK Government tabled three amendments to the Health Bill affecting the statutory framework within which the MHRA operates. Nothing here is law, no regulation is in force, and no medical-device licensing regime exists.
What was tabled
Powers concerning medicines and device information sharing. The practical question is with whom, on what condition, and whether commercially confidential safety signals become shareable across regulators — which is where this connects to regulatory reliance.
Making medicines and device legislation easier to update. This is the delegation question in its clearest form: technical requirements for software and AI-enabled devices change faster than primary legislation can be passed.
Authority supporting development of a future medical-device licensing regime. Supporting the development of a regime is not establishing one: no licensing requirement follows from the amendment as tabled.
The policy question, with the counterargument
Should a medical-device regulator hold a standing statutory power to update technical regulation without fresh primary legislation?
The case for. Device regulation written into statute ages badly. A software-based device can be materially changed by an update that no statutory text anticipated, and a regulator that must wait for a legislative slot regulates last year’s product. Flexible powers also make international convergence practical, because technical requirements can be aligned without each jurisdiction re-legislating.
The case against, which is not procedural fussiness. Rules made under delegated power are harder to contest, cheaper to reverse without notice, and receive less scrutiny than the consequences justify — and the consequences here reach implanted devices and diagnostic software. Parliamentary passage is slow partly because it is adversarial, and adversarial process surfaces objections that a consultation does not. A rule-of-law objection also survives the efficiency argument: manufacturers and patients are entitled to know that the requirements governing a device were made by a body accountable for them.
KPSGILL takes no position on the UK amendments. The comparative interest is that the same trade is live in United States administrative law, moving in the opposite direction.
Comparators
- Pre-market versus post-market surveillance — where device oversight actually happens
- Global regulatory operations — TGA, PMDA, EMA and the reliance pilots
- The 1 September record — what the amendments establish and do not establish